Aileron Therapeutics Inc (NASDAQ:ALRN) shares dropped 5.3% during trading on Thursday . The company traded as low as $0.64 and last traded at $0.72. Approximately 2,575,002 shares changed hands during mid-day trading, an increase of 957% from the average daily volume of 243,671 shares. The stock had previously closed at $0.76.
Several research firms recently weighed in on ALRN. Canaccord Genuity dropped their price objective on Aileron Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. Zacks Investment Research upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday, April 4th. HC Wainwright initiated coverage on Aileron Therapeutics in a report on Monday, March 11th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Aileron Therapeutics in a report on Monday, May 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $4.33.
The company has a debt-to-equity ratio of 0.38, a current ratio of 3.11 and a quick ratio of 3.11. The business’s fifty day simple moving average is $1.01.
In related news, major shareholder Bioventures Ltd Novartis sold 127,150 shares of Aileron Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $1.86, for a total value of $236,499.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.20% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in Aileron Therapeutics stock. Deutsche Bank AG grew its stake in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 432.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,170 shares of the company’s stock after purchasing an additional 104,932 shares during the quarter. Deutsche Bank AG owned 0.88% of Aileron Therapeutics worth $108,000 at the end of the most recent quarter. Institutional investors and hedge funds own 29.17% of the company’s stock.
Aileron Therapeutics Company Profile (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.